Journal Article

Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function

Makavos, George, Βenas, Dimitrios, Lekakis, John, Alexopoulos, Dimitrios, Vlastos, Dimitrios, Triantafyllidi, Helen, Parissis, John, Ikonomidis, Ignatios, Pavlidis, George, Katsimbri, Pelagia, Kostelli, Gavriella, Iliodromitis, Efstathios, Andreadou, Ioanna, Boumpas, Dimitrios, Varoudi, Maria, Tsoumani, Maria

2019

Overview

BackgroundAnakinra, an interleukin-1 receptor antagonist and tocilizumab, an interleukin-6 receptor blocker, are used for the treatment of rheumatoid arthritis. We investigated the differential effects of anakinra and tocilizumab on myocardial and vascular function in an atherosclerosis model of patients with rheumatoid arthritis.Methods120 patients with rheumatoid arthritis were randomized to anakinra (n = 40), tocilizumab (n = 40) or prednisolone (n = 40) for 3 months. Primary outcome measure was the change of left ventricular longitudinal strain after 3 months of treatment. Additionally, we measured coronary flow reserve, flow-mediated dilatation of the brachial artery, carotid-femoral pulse wave velocity, malondialdehyde and protein carbonyls as oxidative stress markers and C-reactive protein blood levels at baseline and post-treatment.ResultsAt baseline, patients among the three treatment arms had similar age, sex, disease activity score and atherosclerotic risk factors. Compared with baseline, all patients had improved longitudinal strain (− 16% vs. − 17.8%), coronary flow reserve (2.56 vs. 2.9), malondialdehyde (2.0 vs. 1.5 µM/L), protein carbonyls (0.0132 vs. 0.0115 nmol/mg), and C-reactive protein post-treatment. In all patients, the percent decrease of malondialdehyde was correlated with percent increase of longitudinal strain (p < 0.001). Compared with tocilizumab and prednisolone, anakinra treatment resulted in a greater improvement of longitudinal strain (18.7% vs. 9.7% vs. 6%) and coronary flow reserve (29% vs. 13% vs. 1%), while pulse wave velocity and brachial blood pressure were improved only after tocilizumab treatment (11 ± 3 vs. 10.3 ± 2 m/s p < 0.05 for all comparisons).ConclusionsAnakinra is associated with an improvement in cardiac function and tocilizumab with improvement in vascular function.Clinical Trial RegistrationURL: https://http://www.clinicaltrials.gov. Unique identifier: NCT03288584.

• Publisher: Springer Nature B.V
• Subject: Arteriosclerosis / Arthritis / Atherosclerosis / Blood levels / Blood pressure / C-reactive protein / Carbonyl compounds / Carbonyls / Cytokines / Femur / Heart / Interleukin 1 / Interleukin 1 receptor antagonist / Interleukin 6 / Interleukins / Malondialdehyde / Oxidative stress / Patients / Prednisolone / Proteins / Rheumatoid arthritis / Risk analysis / Risk factors / Velocity / Ventricle